In Silico Identification of Novel HDAC2 Inhibitors for Reinstating Synaptic wiring in Autism Spectrum Disorder

Samir Abdulkarim Alharbi

Abstract


Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with an increasing incidence rate. For the treatment of ASD, several pharmaceutical approaches, dietary supplements, and behavioral therapy have been proposed, but a definitive cure remains elusive. Histone deacetylases (HDACs) are critical epigenetic regulators whose molecular and pharmacological roles are being studied extensively in medically significant ailments such as neuropsychiatric disorders, neurodegenerative diseases, and cancer on a global scale. HDAC2's specific expression pattern in CNS makes it an appealing therapeutic target for neurological illnesses such as ASD.

Methods: The study used PyRx software (version 0.8) to screen a library of 401 alkaloid compounds against HDAC2. In addition, the DS software was used to predict the physicochemical and DMET properties of the compound library.

Results: Valaciclovir hydrochloride, Dihydrocapsaicin, Guanosine, Santacruzamate A, and 2'-Deoxyguanosine monohydrate compounds exhibited strong interactions with HDAC2. These compounds had a higher binding energy than the control compound, and they have promising drug-like properties and ADMET characteristics.

Conclusion: These identified compounds could be used as HDAC2 inhibitors for the management of ASD, however, experimental research is needed to optimize them as HDAC2 inhibitors.

Keywords: Autism spectrum disorder; Histone deacetylases; Alkaloid compounds; Drug-likeness 


Full Text:

PDF

References


Hodges H, Fealko C, Soares N. Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation. Translational Pediatrics, (2020); 9(Suppl 1): S55-S65.

Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, et al. Global prevalence of autism and other pervasive developmental disorders. Autism Research, (2012); 5(3): 160-179.

Chaplin AV, Polyakova SI, Kochetkova TO, Sokolova SR, Goltsov AY, et al. Noncontiguous finished genome sequence of Megasphaera sp. ASD88, isolated from faeces of a child with autism spectrum disorder. New Microbes and New Infections, (2018); 22: 13-16.

Brondino N, Fusar-Poli L, Rocchetti M, Provenzani U, Barale F, Politi P. Complementary and Alternative Therapies for Autism Spectrum Disorder. Evidence-Based Complementary and Alternative Medicine, (2015); 2015: 258589.

Bang M, Lee SH, Cho SH, Yu SA, Kim K, et al. Herbal Medicine Treatment for Children with Autism Spectrum Disorder: A Systematic Review. Evidence-Based Complementary and Alternative Medicine, (2017); 2017: 8614680.

Tordjman S, Somogyi E, Coulon N, Kermarrec S, Cohen D, et al. Gene x Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Frontiers in Psychiatry, (2014); 5: 53.

Kawanai T, Ago Y, Watanabe R, Inoue A, Taruta A, et al. Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene Expression of Autism-Related Molecules and Delays Neuronal Maturation. Neurochemical Research, (2016); 41(10): 2574-2584.

Wang XM, Gu P, Saligan L, Iadarola M, Wong SSC, et al. Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy. Molecular Cancer Therapeutics, (2020); 19(10): 2196-2209.

Tamanini E, Miyamura S, Buck IM, Cons BD, Dawson L, et al. Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor. ACS Medicinal Chemistry Letters, (2022); 13(10): 1591-1597.

Bernardini S, Tiezzi A, Laghezza Masci V, Ovidi E. Natural products for human health: an historical overview of the drug discovery approaches. Natural Product Research, (2018); 32(16): 1926-1950.

Thomford NE, Senthebane DA, Rowe A, Munro D, Seele P, et al. Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. International Journal of Molecular Sciences, (2018); 19(6): 1578.

Slater O, Kontoyianni M. The compromise of virtual screening and its impact on drug discovery. Expert Opinion on Drug Discovery, (2019); 14(7): 619-637.

Maia EHB, Assis LC, de Oliveira TA, da Silva AM, Taranto AG. Structure-Based Virtual Screening: From Classical to Artificial Intelligence. Frontiers in Chemistry, (2020); 8343.

Kireev D. Structure-Based Virtual Screening of Commercially Available Compound Libraries. Methods in Molecular Biology, (2016); 1439: 65-76.

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2015); 1263: 243-250.

Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Current Treatment Options in Neurology, (2010); 12(6): 529-538.

Accordino RE, Kidd C, Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Expert Opinion on Pharmacotherapy, (2016); 17(7): 937-952.

Nazeer A. Psychopharmacology of autistic spectrum disorders in children and adolescents. Pediatric Clinics of North America, (2011); 58(1): 85-97.

Boon-Yasidhi V, Jearnarongrit P, Tulayapichitchock P, Tarugsa J. Adverse effects of risperidone in children with autism spectrum disorders in a naturalistic clinical setting at siriraj hospital, Thailand. American Journal of Psychiatry, (2014); 2014: 136158.

Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America, (2008); 17(4): 803-820.




DOI: http://dx.doi.org/10.62940/als.v11i2.2701

Refbacks

  • There are currently no refbacks.